Monograph Details
|
|
Neoplasms
> Hormones and antagonists
|
|
ELIGARD 22.5mg 3-MONTH |
| Manufacturer |
|
Sanofi Aventis |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
GnRH analogue. |
| Generic Name |
|
Leuprolide acetate 22.5mg per inj; ext-rel susp; for SC inj. |
| Also |
• ELIGARD 30mg 4-MONTH
• ELIGARD 45mg 6-MONTH
• ELIGARD 7.5mg 1-MONTH
|
| Indications |
|
Palliative treatment of advanced prostate cancer. |
| Children |
|
See Contraindications. |
| Adults |
|
Allow product to reach room temperature before using; inject within 30 minutes of mixing. Use correct formulation. 7.5mg SC once per month; or 22.5mg SC once every 3 months; or 30mg SC once every 4 months; or 45mg SC once every 6 months. Rotate inj site. |
| Contraindications |
|
Women. Children. Pregnancy (Cat.X). |
| Precautions |
|
May worsen metastatic vertebral lesions and/or urinary tract obstruction; monitor closely during first few weeks. Monitor serum testosterone, PSA. |
| Adverse Reactions |
|
Hot flashes/sweats, testicular atrophy, gynecomastia, local reactions, asthenia, pain, spinal cord compression, decreased bone density; transient worsening of signs/symptoms (eg, bone pain, urinary tract obstruction, neuropathy, hematuria). |
| How Supplied |
|
Single-use kit—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
